Patent 10428045 was granted and assigned to Silverback Therapeutics, Inc. on October, 2019 by the United States Patent and Trademark Office.
Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.